Anterior chamber paracentesis might prevent sustained intraocular pressure elevation after intravitreal injections of ranibizumab for age-related macular degeneration.
OBJECTIVE
To evaluate the efficacy of anterior chamber paracentesis for preventing sustained intraocular pressure (IOP) elevation after intravitreal ranibizumab (IVR) injections for age-related macular degeneration (AMD).


METHODS
The medical records for all cases of exudative AMD treated with IVR injections and followed monthly for 12 months or longer were reviewed retrospectively. Anterior chamber paracentesis was performed just before IVR injections. A sustained IOP elevation was defined as 22 mm Hg or higher during 2 consecutive visits with an increase exceeding 6 mm Hg from baseline.


RESULTS
One hundred and eleven eyes met the inclusion criteria, and none of these eyes had a sustained IOP elevation.


CONCLUSIONS
Anterior chamber paracentesis before IVR injections may prevent sustained IOP elevations.
Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan.
Yusuke
Y
Ichiyama
Tomoko
T
Sawada
Masashi
M
Kakinoki
Osamu
O
Sawada
Tomoko
T
Nakashima
Yoshitsugu
Y
Saishin
Hajime
H
Kawamura
Masahito
M
Ohji
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000867:Anterior Chamber / Q000502:physiology; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007429:Intraocular Pressure; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000517:prevention & control*; D019152:Paracentesis; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D057135:Wet Macular Degeneration / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab